NASDAQ: CELU
Celularity Inc Stock

$1.49+0.01 (+0.68%)
Updated Apr 30, 2025
CELU Price
$1.49
Fair Value Price
N/A
Market Cap
$33.50M
52 Week Low
$1.00
52 Week High
$5.22
P/E
-1.26x
P/B
1.94x
P/S
1.35x
PEG
N/A
Dividend Yield
N/A
Revenue
$48.20M
Earnings
-$35.05M
Gross Margin
56.8%
Operating Margin
-62.09%
Profit Margin
-72.7%
Debt to Equity
6.46
Operating Cash Flow
-$12M
Beta
1.06
Next Earnings
N/A
Ex-Dividend
N/A
Next Dividend
N/A

CELU Overview

Celularity Inc., a clinical-stage biotechnology company, develops off-the-shelf placental-derived allogeneic cell therapies for the treatment of cancer, immune, and infectious diseases. It operates through three segments: Cell Therapy, Degenerative Disease, and BioBanking. The company's lead therapeutic programs include CYCART-19, a placental-derived CAR-T therapy, which is in Phase I clinical trial for the treatment of B-cell malignancies; CYNK-001, placental-derived unmodified natural killer (NK) cell that is in Phase I clinical trial to treat acute myeloid leukemia, as well as in Phase I/IIa clinical trial for the treatment of glioblastoma multiforme and COVID-19; CYNK-101, an allogeneic genetically modified NK cell, which is in Phase I clinical trial to treat HER2+ gastric and gastroesophageal cancers; APPL-001, a placenta-derived mesenchymal-like adherent stromal cell that is in a pre-clinical stage for the treatment of Crohn's disease; and PDA-002, a placenta-derived mesenchymal-like adherent stromal cell, which is in pre-clinical stage for the treatment of facioscapulohumeral muscular dystrophy. It also sells and licenses products that are used in surgical and wound care markets, such as Biovance and Interfyl; collects stem cells from umbilical cords and placentas; and provides cells storage under the LifebankUSA brand. The company was incorporated in 2016 and is headquartered in Florham Park, New Jersey.

Zen Rating

Our proven quant model uses 115 proprietary factors, including AI, to determine CELU's potential to beat the market

DSell
  • Stocks with a Zen Rating of Sell (D) had an average loss of -4.50% per year. Learn More

Zen Rating Component Grades

F
Zen Rating uses advanced AI algorithms that detect subtle patterns in market data; it anticipates future trends that point to superior stock price results.

Industry: Biotech

Industry Rating
F
CELU
Ranked
#233 of 462

Top Ranked Stocks in Industry

View Top Biotech Stocks

Be the first to know about important CELU news, forecast changes, insider trades & much more!

CELU News

Overview

Due Diligence Score

Industry Average (24)
You've viewed Due Diligence Score for 10/10 free stocks. Upgrade to Premium to see how CELU scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.

Due Diligence Checks

CELU is unprofitable, so we are unable to calculate its intrinsic value according to an updated version of Benjamin Graham's Formula from "The Intelligent Investor"
Below Benjamin Graham Formula Value Valuation
CELU is good value based on its book value relative to its share price (1.94x), compared to the US Biotechnology industry average (4.45x)
P/B vs Industry Valuation
CELU is unprofitable, so we... subscribe to Premium to read more.
PEG Value Valuation
There are 30 more CELU due diligence checks available for Premium users.

Valuation

CELU price to earnings (PE)

For valuing profitable companies with steady earnings

Company
-1.26x
Industry
-162.28x
Market
29.18x

CELU price to book (PB)

For valuing companies that are loss-making or have lots of physical asset

Company
1.94x
Industry
4.45x
CELU is good value based... subscribe to Premium to read more.
P/B vs Industry Valuation

CELU's financial health

Profit margin

Revenue
$9.3M
Net Income
-$16.1M
Profit Margin
-173.2%
CELU's cash burn is expected... subscribe to Premium to read more.
Interest Coverage Financials
CELU's profit margin has increased... subscribe to Premium to read more.
Profit Margin Growth Financials

Assets to liabilities

Assets
$128.8M
Liabilities
$111.6M
Debt to equity
6.46
CELU's short-term liabilities ($76.17M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
CELU's long-term liabilities ($35.39M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
CELU's debt has increased relative... subscribe to Premium to read more.
Shrinking Debt Financials
CELU's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials

Cash flow

Operating
-$144.0k
Investing
-$35.0k
Financing
-$79.0k
CELU's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials

CELU vs Biotech Stocks

TickerZen RatingMarket Cap1d %P/EP/B
CELUD$33.50M+0.68%-1.26x1.94x
OKURD$33.46M-1.58%-0.16x0.32x
PLUR$33.73M+3.95%-1.31x-4.20x
FGEN$34.11M+3.05%-0.70x-0.15x
ALGSC$34.12M+6.29%-0.27x-1.18x

Celularity Stock FAQ

What is Celularity's quote symbol?

(NASDAQ: CELU) Celularity trades on the NASDAQ under the ticker symbol CELU. Celularity stock quotes can also be displayed as NASDAQ: CELU.

If you're new to stock investing, here's how to buy Celularity stock.

What is the 52 week high and low for Celularity (NASDAQ: CELU)?

(NASDAQ: CELU) Celularity's 52-week high was $5.22, and its 52-week low was $1.00. It is currently -71.46% from its 52-week high and 48.85% from its 52-week low.

How much is Celularity stock worth today?

(NASDAQ: CELU) Celularity currently has 22,484,239 outstanding shares. With Celularity stock trading at $1.49 per share, the total value of Celularity stock (market capitalization) is $33.50M.

Celularity stock was originally listed at a price of $100.60 in May 21, 2019. If you had invested in Celularity stock at $100.60, your return over the last 5 years would have been -98.52%, for an annualized return of -56.94% (not including any dividends or dividend reinvestments).

How much is Celularity's stock price per share?

(NASDAQ: CELU) Celularity stock price per share is $1.49 today (as of Apr 30, 2025).

What is Celularity's Market Cap?

(NASDAQ: CELU) Celularity's market cap is $33.50M, as of May 1, 2025.

Market cap (market capitalization) is the total market value of a publicly traded company's outstanding shares.

Celularity's market cap is calculated by multiplying CELU's current stock price of $1.49 by CELU's total outstanding shares of 22,484,239.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.